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ABSTRACT: The development of an effective HIV vaccine
continues to be a major health challenge since, so far, only
the RV144 trial has demonstrated a modest clinical
efficacy. Recently, the targeting of the 12 highly conserved
protease cleavage sites (PCS1−12) has been presented as a
strategy seeking to hamper the maturation and infectivity
of HIV. To pursue this line of research, and because
peptide antigens have low immunogenicity, we have
included these peptides in engineered nanoparticles,
aiming at overcoming this limitation. More specifically,
we investigated whether the covalent attachment of a PCS
peptide (PCS5) to polysaccharide-based nanoparticles, and
their coadministration with polyinosinic:polycytidylic acid
(poly(I:C)), improved the generated immune response. To this end, PCS5 was first conjugated to two different
polysaccharides (chitosan and hyaluronic acid) through either a stable or a cleavable bond and then associated with an
oppositely charged polymer (dextran sulfate and chitosan) and poly(I:C) to form the nanoparticles. Nanoparticles
associating PCS5 by ionic interactions were used in this study as the control formulation. In vivo, all nanosystems elicited
high anti-PCS5 antibodies. Nanoparticles containing PCS5 conjugated and poly(I:C) seemed to induce the strongest
activation of antigen-presenting cells. Interestingly, T cell activation presented different kinetics depending on the
prototype. These findings show that both the nanoparticle composition and the conjugation of the HIV peptide antigen
may play an important role in the generation of humoral and cellular responses.
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With almost 2 million newly infected individuals peryear, HIV continues to be one of the mostimportant global health challenges.1 Despite the
efforts dedicated to the discovery of an effective vaccine against
this virus, the most positive results achieved so far are those
reported in the RV144 vaccine (Phase III clinical trial), which
conferred a modest 30% protection against the infection.2 This
protection was associated with the ability of the vaccine to
generate weakly neutralizing and non-neutralizing antibody
responses.3 It is also worth noting that the efficacy of this trial
declined from 60 to 30% from 42 to 60 months after
administration, which further underscores the need for HIV
vaccine designs that would efficiently induce protective and
long-lasting immune responses. This efficiency depends, to a
great extent, on the adequate combination of antigen and
adjuvant.4,5
Considering how the natural immunity to HIV-1 works, the
peptide sequences around the protease cleavage sites (PCS)
have been proposed as targets for a candidate vaccine against
HIV. The protease is an essential enzyme for the HIV virus
because its function is to cleave specific proteins, such as Gag,
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Gag-Pol, and Nef, that are essential for the maturation of HIV
virions and, thus, crucial to its infectivity.6−8 The proteolysis of
these proteins must take place on the 12 cleavage sites in a
controlled and sequential way, and the interruption of this
process, even in one single site, may interrupt virus maturation
and, therefore, stop virus infection.6,7,9 In addition, these sites
are highly conserved among HIV-1 viruses, which could help
overcome the problems associated with the HIV virus high-
sequence diversity and rapid mutation rates.
A wide variety of nanosystems are currently under evaluation
for their ability to deliver vaccine immunogens to protect the
antigens from degradation and facilitate their internalization by
the target immune cells.10 In addition, it has been reported that
the response to antigen-loaded nanocarriers may be influenced
by their composition and physicochemical properties.10−12
Among these nanocarriers, chitosan (CS)-based nanosystems
have been widely employed as antigen carriers through both
parenteral and mucosal routes.13 In fact, CS is a biodegradable
and biocompatible polymer, with a FDA GRAS status, which
has already been approved for dietary use and as a wound-
dressing material.14,15 Our group has originally reported the
development of CS nanoparticles (NPs)16 and nanocapsules
(NCs)17 and assessed their potential to generate humoral
responses against different antigens, such as the recombinant
hepatitis B surface antigen (rHBsAg), the tetanus toxoid, and
IutA antigen from E. coli.18−21 Other studies have also shown
promising results when using CS-based nanosystems in order
to enhance T cell responses.22,23
A critical aspect that has not been completely elucidated is
the influence of the antigen−nanocarrier interaction on the
nature of the immune response generated. In some studies, the
association of antigens to nanocarriers has relied on simple
physical entrapment techniques or the establishment of ionic
or hydrophobic forces,24−26 whereas in others the association
involved the chemical conjugation of the antigens to the
nanosystems.27−37 In the later studies, chemical conjugation
was shown to increase the humoral response when compared
to other types of antigen association.31,32,36,37 More specifi-
cally, a study performed for a malaria antigen showed that
these improved humoral responses were caused by an
increased interaction of the antigen with the B-cell receptor
when the antigen was covalently attached to the surface of lipid
NCs.32 Similarly, the covalent attachment of an HIV protein
antigen to virus-like particles resulted in an efficient generation
of the specific humoral and CD8+ T-cell responses.30
On the other hand, over the past decade it has become
evident that the coencapsulation of antigens and adjuvants,
such as the Toll-like receptor (TLR) agonists, further improves
the performance of antigen-loaded nanosystems in vaccina-
tion.10 Furthermore, it has been reported that these TLR
molecules are able to direct the immune response toward
either humoral or cellular profiles.20,26,38
On the basis of this background information, the primary
objective of this work was to evaluate if the chemical linkage of
an SIV PCS peptide antigen (PCS5) to polysaccharide NPs
and the inclusion of poly(I:C), could improve its immunoge-
nicity over the association by ionic forces to NPs. We
hypothesized that the conjugation of the antigen to the
polysaccharides might prevent its release until the particles are
engulfed and processed by antigen presenting cells (APCs),
thereby dually improving and prolonging the induced immune
responses. CS and hyaluronic acid (HA) were the poly-
saccharides of choice to conjugate the peptide antigen PCS5.
In addition, the TLR3 agonist poly(I:C) was included in these
two nanosystems to stimulate a cellular response against the
antigen. As the control formulation, PCS5 was entrapped by
ionic forces in NPs of CS and dextran sulfate (DS), which were
previously reported as good antigen carriers for PCS peptide
antigens.39 Polymer−PCS5 conjugates and the resulting NPs
were characterized in terms of their chemical composition and
structural organization. Finally, their capacity to activate the
immune system, regarding antibody production, T cell and
APCs activation, and generation of central and effector
memory T cells in mice, was studied.
RESULTS AND DISCUSSION
Developing an effective HIV vaccine has proved to be
particularly challenging due to the special characteristics of
this virus. On the one hand, the virus infects CD4+ T cells,
which have an important role in the development of the
adaptive immune response. On the other hand, it mutates
rapidly, leading to a deleterious activation of the immune
system, which results in the generation of ineffective humoral
and cellular responses. In addition, the different virus strains
are highly variable, a fact that complicates the generation of
broad and protective immune responses.5 Our approach for
the design of an HIV vaccine has been to use the peptide
sequences that overlap the 12 HIV PCS as antigens. For the
generation of infective virions, these HIV PCS sites have to be
cleaved sequentially; thus, if a single proteolytic reaction is
disrupted, the whole process could fail. An additional
advantage of the PCS peptide antigens relies on the fact that
these PCS are highly conserved regions among HIV-1 viruses,
and therefore, the mutation of the virus will not diminish the
activity of the vaccine.6−9 In a prior approach, these peptide
antigens were entrapped into CS/DS NPs and administered to
nonhuman primates, which had already been primed with the
PCS1−12 encoding plasmids cloned into viral vectors. The
results showed a significant increase in the IgG responses
against PCS after nasal boosting with the nanoparticles.39
Based on these preliminary findings, we sought to further
improve the immunogenicity of our PCS antigens by exploring
different NPs-based formulation strategies to deliver the
peptide antigen. For this purpose, the PCS5 antigen was
selected for its association to the nanosystems, based on the
premise that one cleavage error could interrupt virus
maturation. PCS5 was first conjugated to two different
polysaccharides, CS and HA, and the resulting conjugate was
used to form NPs by ionic interaction with an oppositely
charged polymer (CS−PCS5/DS and CS/HA−PCS5 NPs).
The TLR3 agonist, poly(I:C), was also associated with these
NPs in order to evaluate its effect on the cellular immune
response generated by the NPs. The already reported CS/DS
NPs with PCS5 physically entrapped were used as the control
formulation. These strategies were based on the hypothesis
that conjugation of PCS5 peptide antigen to the matrix-
forming polymer would facilitate the intracellular delivery of
the antigen with the subsequent improvement of the humoral
and cellular immune responses. In addition, poly(I:C) was
expected to boost the activation of APCs, effector and memory
T cells.
Development of Peptide-Loaded Polysaccharide
NPs. Polysaccharides, particularly CS, have attracted signifi-
cant attention as biomaterials for the design of antigen delivery
carriers.13,40,41 Our group has originally reported the develop-
ment of NPs and NCs made of CS16,17 for the delivery of a
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variety of antigens (e.g., tetanus toxoid, rHBsAg, influenza, E.
coli antigen, and also peptide antigens) through different routes
of administration.18,19,24,42,43 Other authors have also disclosed
the utility of nanosystems made of DS13,44−46 or HA,47−52
both negatively charged polysaccharides, to induce immune
responses. In most of these reports, the association of the
antigen to the polymeric nanocarrier was based on a simple
entrapment process, normally driven by ionic interactions
between the polymers and the antigen. However, in this work
our objective was to covalently conjugate the PCS5 peptide
antigen to the NPs in order to achieve a more sustained and
improved presentation of the antigen to the immune cells.
Apart from selecting the biomaterials to form the antigen
nanocarriers, we also chose an adjuvant, the TLR3 agonist
poly(I:C). This molecule mimics viruses dsRNA and activates
TLR3 inducing robust cytokine and chemokine re-
sponses.43,53−55 With these components, we designed three
different nanosized systems, where the antigenic peptide PCS5
was either (i) entrapped into the CS/DS NPs, as the control
formulation, (ii) covalently linked to CS, or (iii) covalently
linked to HA; prior to the formation of the NPs by adjusting
the ionic interaction of CS with DS or HA (Figure 1).
Preparation of CS/DS + PCS5 NPs. Using the
preparation method for CS/DS NPs previously described by
our laboratory,39 PCS5 was easily entrapped within CS/DS
nanoparticles by simply adjusting the ionic interaction of the
cationic peptide (PCS5) and the cationic polysaccharide (CS)
with the negatively charged polysaccharide (DS) (Figure 1A).
The mass ratio 1:3 CS:DS resulted in adequate physicochem-
ical properties, association efficiency (80 ± 8%), and antigen
loading (8%). This apparent excess of DS was required to
complex efficiently the cationic peptide. The resulting NPs had
a particle size of approximately 120 nm, a low polydispersity,
and a negative ζ-potential (Table 1).
Preparation of CS−PCS5/DS/pIC NPs. PCS5 peptide
was conjugated to CS by an oxime bond, as schematically
represented in Figure 2Ai. 1H NMR analysis led to the
identification of the signal peaks of the aromatic rings and
isopropyl groups of PCS5 (in blue), together with specific
signal peaks of CS’s glucosamine units (orange arrows), which
confirms the chemical conjugation of peptide and polymer.
The substitution degree, assessed using a colorimetric assay,
was of 2.6 mol of PCS5 per mol of CS (14% in weight).
The CS−PCS5 conjugate was then used to form NPs
through ionic interaction with DS. In addition, poly(I:C) was
also incorporated into the NPs to increase its immunostimu-
latory properties. NPs with adequate final antigen loading
(5%), and poly(I:C) loading (0.3%) could be obtained when
the CS:DS (w/w) ratio was 2:1 (Figure 1B). The resulting
NPs had a particle size of 140 nm, with low polydispersity and
positive surface charge (Table 1). This positive charge was
attributed to a certain excess of CS conjugated with the
peptide, since increasing amounts of DS caused a decrease in
the surface charge (Supporting Information, Figure S1A).
Preparation of CS/HA−PCS5/pIC NPs. The conjugation
of PCS5 to HA was achieved through the formation of a
thioether bond, which has been reported to be cleaved in
glutathione-rich environments, such as the cytosol.56 In this
case, thiol−maleimide chemistry was employed to link PCS5
to HA (Supporting Information, Figure S2). The results of the
1H NMR and DOSY analyses allowed us to evaluate the
peptide conjugation reaction and its yield. As shown in Figure
2Bii, the NMR spectrum of the conjugate exhibits the
characteristic peaks of PCS5 (blue arrows), and those
corresponding to the acetyl groups of HA (orange arrows).
The substitution degree calculated by NMR was of 3.8 mol of
PCS5 per mol of HA (15.9% in weight). On the other hand,
DOSY analysis showed a diffusion coefficient for the conjugate
of 9.5 × 10−8 cm2/s, similar to the one for HA (8.8 × 10−8
cm2/s) and much lower than the one observed for the free
PCS5 (8.4 × 10−7 cm2/s) (Supporting Information, Figure
S3), confirming the conjugation of the peptide to the polymer.
Prior to the formation of the NPs using the HA−PCS5
conjugate, a screening of blank CS/HA NPs was conducted to
select the most adequate polymer ratio combination
(Supporting Information, Figure S1B). A surface charge switch
from positive to negative values was observed when the mass
ratio CS:HA decreased. For this reason, a mass ratio CS/HA
Figure 1. Composition of the different prototypes developed in
this work. Schematic representation of the preparation process for
the three developed nanosystems. (A) CS/DS + PCS5 NPs, (B)
CS−PCS5/DS/pIC NPs, and (C) CS/HA−PCS5/pIC NPs. Key:
CS, chitosan; DS, dextran sulfate; PCS5, protease cleavage site 5;
NPs, nanoparticles; pIC, poly(I:C) (polyinosinic:polycytidylic
acid); HA, hyaluronic acid.














119 ± 7 0.15 −50 ± 3 7.9 N/A
CS−PCS5/
DS/pIC
141 ± 6 0.17 +29 ± 3 4.9 0.3
CS/HA−
PCS5/pIC
211 ± 15 0.07 +30 ± 1 4.6 0.05
aMean ± S.D., n ≥ 3. Key: CS, chitosan; DS, dextran sulfate; PCS5,
protease cleavage site 5; NPs, nanoparticles; pIC, poly(I:C); HA,
hyaluronic acid; PDI, polydispersity index.
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1:1 was selected to form these NPs, since their positive surface
charge was expected to allow the association of the negatively
charged poly(I:C) to the system (Figure 1C). The final NPs
had a particle size of approximately 200 nm and a positive
surface charge of +30 mV (Table 1). Adequate loading values
for PCS5 (5%) and poly(I:C) (0.05%) were also achieved
(Table 1).
Morphological Analysis of the Nanosystems. Field
emission scanning electron microscopy (FESEM) images from
the NPs were taken for each nanosystem using the STEM and
InLens detectors (Figure 3). In all cases, a spherical particle
shape could be observed, as well as diameters similar to the
ones reported by DLS analysis (Table 1).
Structural Distribution of PCS5 in CS/HA−PCS5/pIC
NPs. XPS analysis was also used to characterize the surface
composition of this nanocarrier. The amount of sulfur present
on CS/HA−PCS5/pIC NPs (1.15%) was higher than the one
observed in blank CS/HA/pIC NPs (0.28%), which indicates
that PCS5 (2.05% of sulfur) must be present on the external
layers of the NPs (Supporting Information, Table S1).
Similarly, the ratios C/O and C/N determined for CS/HA−
PCS5/pIC NPs (3.19 and 9.31, respectively) were closer to
those of PCS5 (3.50 and 3.66) than to those observed in the
blank CS/HA/pIC NPs (1.87 and 12.86), further confirming
the prevalent presence of PCS5 on the surface of the NPs.
On the other hand, the binding energy of an element is very
sensitive to its chemical environment, and it can be used as the
fingerprint of a compound. Thus, we compared the required
energy to extract one electron from the carbon 1s orbital of
PCS5, CS/HA/pIC, and CS/HA−PCS5/pIC NPs (Support-
ing Information, Figure S4). The obtained profiles indicated
that the binding energies of PCS5 alone and CS/HA−PCS5/
pIC were very similar, as additional proof that PCS5 was
present on the surface of the NPs. This structural organization
could facilitate the presentation of the antigen to B cells, and
increase the humoral response against it, as already reported
for similar antigen presentations.32,34
PCS5 Release When Covalently Attached to NPs. In
the present work, we also compared the influence of different
covalent attachments in the generation of the immune
response. In this regard, a noncleavable bond (oxime bond,
in the CS−PCS5 conjugate) and a cleavable one (thioether
bond, in HA−PCS5 conjugate) were evaluated. In the case of
the CS−PCS5 conjugate (Figure 2Ai), the oxime bonds have
been reported as highly stable linkages at physiological
pHs.57−59 Therefore, this linkage would be the model for a
long-lasting attachment of the peptide antigen, which would
only be released after being processed by APCs.
On the other hand, thioether bonds are known to undergo
retro-Michael reactions in the presence of free thiols,33,56,60
which are presented in great amounts in the cytosol of cells as
part of glutathione (GSH) molecules. To demonstrate this
hypothesis, NPs were incubated in phosphate buffered saline
(PBS), alone or with a 10 mM GSH concentration for up to 8
h at 37 °C. As shown in Figure 4, almost no PCS5 was
detected upon incubation in PBS, however, upon incubation in
a GSH-rich medium, PCS5 was immediately released from the
NPs. These results indicate that the release of the peptide is
triggered by GSH and led us to speculate that the peptide will
not be released in the extracellular medium, but only in the
intracellular compartments where high concentrations of GSH
are present.61,62
Freeze-Drying Preserves NP Properties and Allows
Long-Term Storage. A key feature of vaccine formulations is
their stability during storage. Thus, in order to improve the
long-term stability of the antigen-loaded NPs, the different
formulations were freeze-dried using different cryoprotectants.
The results of the screening of the freeze-drying conditions led
to the selection of trehalose 7% for both CS/DS + PCS5 and
CS/HA−PCS5/pIC NPs and 4% for the CS−PCS5/DS/pIC
Figure 2. Chemical characterization of polymer−PCS5 conjugates.
(A) CS−PCS5 final conjugate, (i) schematically represented, (ii)
1H NMR of CS, PCS5, and CS−PCS5 conjugate. Blue arrows
indicate the signals from the aromatic rings and isopropyl groups
of PCS5 and orange arrows the glucosamine units of CS, both
observed in the NMR of the conjugate. (B) HA−PCS5 conjugate
(i) schematically represented, (ii) 1H NMR of HA, PCS5, and
HA−PCS5 conjugate. These results corroborated the presence of
both the PCS5 characteristic signals (blue arrows) and the acetyl
groups of HA (orange arrows) in the conjugate. Key: CS, chitosan;
PCS5, protease cleavage site 5; HA, hyaluronic acid.
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NP formulation. These conditions guaranteed the preservation
of the original properties of the formulations (Figure 5). When
stored at 4 °C, these freeze-dried formulations maintained PDI
and surface charge stable for at least 18 months, while particle
size slightly increased.
In Vivo Antibody Responses. To evaluate the in vivo
activity of the different PCS5-loaded prototypes, freeze-dried
formulations were resuspended in water, and 50 μL of this
suspension (containing a PCS5 dose of 5 μg) was intra-
muscularly injected to BALB/c mice. A group of non-
vaccinated animals was used as control. Animals were
vaccinated three times, as shown in Figure 6A.
Figure 6B shows the evolution of the anti-PCS5 IgG levels
over time. Overall, the IgG responses elicited by the three
different NP formulations increased significantly over time,
reaching their maximum values at the latest time point in the
experiment (week 16). At this time point, the amount of anti-
PCS5 antibodies detected in all NPs was three times higher
than the levels detected in unvaccinated mice. This increasing
and prolonged immunogenic response is of particular interest
in the design of an HIV vaccine because persistent levels of
antibodies are essential for an effective vaccination.63 This
response is also in agreement with previous data reported by
our group that showed the capacity of the antigen-loaded NPs
to induce significant IgG levels up to 28 or 37 weeks after
immunization.20,25 Considering these previous results, it is
possible that the antigen-loaded NPs could still produce
important levels of antibodies beyond the 16 weeks considered
in our study.
In addition to eliciting a strong and maintained immune
response, the results of this study also indicate that the
covalent linkage between the peptide and the NPs does not
have an effect on the humoral responses. This is in contrast
with previous findings where antigen conjugation improved
humoral response when compared to simple ionic inter-
actions.31,32
In Vivo Cellular Activation. To evaluate the changes in T
cell subsets and the cellular activation of different immune cells
upon vaccination, splenocytes from naiv̈e or NP-vaccinated
mice were stained and analyzed for different T cell and
monocyte/macrophage phenotyping markers. Multicolor flow
cytometry gating strategy used for phenotyping is summarized
in the Supporting Information, Figure S5.
Monocytes and macrophages are APCs that process and
present pathogen-derived antigens to T cells. Depending on
their function, murine monocytes can be further divided as
Ly6chi and Ly6clow, with the former being the classical pro-
inflammatory and phagocytic monocytes and the latter the
nonclassical or patrolling monocytes.64−66 Thus, the greater
the activation of these APCs, the higher the capacity to recall
other cellular populations and to stimulate the immune system.
Splenocytes were stained with markers for phenotyping
Figure 3. Morphological characterization of the developed nanosystems. Field emission scanning electron microscopy (FESEM) images of
(A) CS/DS + PCS5 NPs, (B) CS−PCS5/DS/pIC NPs, and (C) CS/HA−PCS5/pIC NPs with the (i) STEM and (ii) InLens detectors. Scale
bar: 200 nm. Key: CS, chitosan; DS, dextran sulfate; PCS5, protease cleavage site 5; pIC, poly(I:C) (polyinosinic:polycytidylic acid); HA,
hyaluronic acid; STEM, scanning transmission electron microscopy; InLens, immersion lens.
Figure 4. PCS5 release from CS/HA−PCS5/pIC NPs in a thiol-
rich PBS solution (GSH 10 mM) in comparison to only PBS. Key:
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monocytes subsets Ly6chi and Ly6clow and markers for
characterizing macrophages (CD11b+ CD11c− F4/80+) to
identify the different subsets (Supporting Information, Figure
S5A). To investigate if the nanosystems were able to activate
these subpopulations, the expression of the costimulatory
signals CD40+ and CD86+, both involved in the T-cell
activation process,67−69 was measured. Regarding CD40+
expression, the highest activation of Ly6chi, Ly6clow, and
macrophages by CS/HA−PCS5/pIC NPs took place 9 weeks
post prime (Figure 7). However, this expression decreased
slightly during the subsequent weeks (Supporting Information,
Figure S6). For CS/DS + PCS5 and CS−PCS5/DS/pIC NPs,
the number of monocytes and macrophages expressing CD40+
was lower than in the prototype containing HA, but the
response remained for a longer period of time. In the case of
CD86+ monocytes and macrophages, the values mirrored the
ones for CD40+, with the difference that at later time points
the values were similar to those found in naiv̈e mice
(Supporting Information, Figure S6). Overall, the prototypes
of CS/HA−PCS5/pIC NPs and CS−PCS5/DS/pIC NPs
Figure 5. Freeze-dried stability of the developed nanosystems. Evolution of the particle size and the surface charge of the freeze-dried (A)
CS/DS + PCS5 NPs, (B) CS−PCS5/DS/pIC NPs and (C) CS/HA−PCS5/pIC NPs during storage. Key: CS, chitosan; DS, dextran sulfate;
PCS5, protease cleavage site 5; NPs, nanoparticles; pIC, poly(I:C) (polyinosinic:polycytidylic acid); HA, hyaluronic acid; FD, freeze-dried.
Figure 6. In vivo studies in mice. (A) Schematic representation of the study design and timeline of the analysis. (B) Anti-PCS5 antibody
levels after the intramuscular administration of the three nanoformulations CS/DS−PCS5 (black bars), CS−PCS5/DS/pIC (white bars),
and CS/HA−PCS5/pIC (gray bars) to 50 mice per group. Values represent mean ± SEM (n ≥ 5). Statistical comparison between groups
was done using a Mann−Whitney test. Significant statistical differences are represented as * (p < 0.05), ** (p < 0.01), *** (p < 0.001), and
**** (p < 0.0001) for comparison between groups and to naiv̈e mice. Mouse and syringe images in (A) were reproduced from Servier
Medical Art under a Creative Commons Attribution 3.0 Unported License, https://creativecommons.org/licenses/by/3.0. Key: NPs,
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elicited the highest stimulation of the monocyte/macrophage
lineage (Figure 7, and Supporting Information, Figure S6),
which might be caused by the covalent conjugation of the
peptide antigen, in accordance with our hypothesis. In
addition, we cannot discard the potential role of poly(I:C) in
the stimulation process.70
In a second set of experiments and in order to further assess
the activation of T cells, the secretion of two cytokines that
influence anti-HIV responses, i.e., interleukin 2 (IL-2) and
tumor necrosis factor α (TNFα),71 was measured. IL-2 is
involved in T-cell proliferation and expansion,72 while TNFα is
a pro-inflammatory cytokine that participates in innate and
adaptive immune responses.73−75 We also aimed at evaluating
the kinetics of T cell activation over time, bearing in mind that
an immediate high T cell response would not necessary
translate into the best protection. The results showed that the
three prototypes were able to activate both CD4+ and CD8+ T
cells with different cytokine secretion kinetics. The highest
overall secretion was observed for CS/DS + PCS5 NPs at 10
weeks. In the case of CS−PCS5/DS/pIC NPs, the highest
secretion of both IL-2 and TNFα was observed at 9 weeks and
16 weeks post prime (Figure 8), whereas in the case of CS/
HA−PCS5/pIC NPs, this activation was more sustained at
12−16 weeks (Figure 8). This pattern could be caused by the
different release profiles of the antigen from the NPs, as
previously discussed. It is also worth mentioning that delayed
T cell activation observed here has also been recently described
for an mRNA-based vaccine,76 a result that raises questions
regarding the ideal T cell activation profile. The way this T cell
activation profile correlates with efficacy will be a matter of
further investigation, preferably in larger animal models.
Besides effector T cells, the generation of memory T cells by
vaccines is also important to guarantee long-term responses
against infections.77 Depending on the expression of the
homing marker L-selectin (CD62L), CD4+ and CD8+ memory
T cells can be further divided as central memory T cells (TCM;
CD44+ CD62L+) and effector memory T cells (TEM; CD44
+
CD62L−). Regarding their role in the immune response, TCM
are important for the stimulation of dendritic cells and B cells
and also because they help expand the effector T cell subsets
once they have encountered the antigen. On the other hand, in
the same situation, TEM rapidly convert to effector cells to fight
Figure 7. Monocyte and macrophage expression of costimulatory factors. CD40+ and CD86+ expression in (A, B) Ly6Clow monocytes; (C, D)
Ly6Chigh monocytes, and (E, F) macrophages at 9 weeks post prime was quantified by multicolor flow cytometry of splenocytes obtained
from nontreated naiv̈e (red bars) and NP-vaccinated mice: CS/DS + PCS5 (black bars), CS−PCS5/DS/pIC (white bars), or CS/HA−PCS5/
pIC (gray bars). Values represent mean ± SEM (n ≥ 3). Statistical comparison between groups was done using a Mann−Whitney test.
Significant statistical differences are represented as * (p < 0.05) and ** (p < 0.01) for comparison between groups and to naiv̈e mice. Key:
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against the infection.78,79 Hence, our objective was to assess if
the three nanoformulations under study were able to increase
both types of memory T cells, thereby ensuring a good
immune response upon infection. The results in Figure 9
Figure 8. CD4+ and CD8+ T-cell activation. IL-2 and TNFα secretion in (A, C) CD4+ and (B, D) CD8+ T cells was quantified by multicolor
flow cytometry of T-cells derived from splenocytes from nontreated naiv̈e (red bars) and NP-vaccinated mice: CS/DS + PCS5 (black bars),
CS−PCS5/DS/pIC (white bars) or CS/HA−PCS5/pIC (gray bars). Values represent mean ± SEM (n ≥ 3). Statistical comparison between
groups was done using a Mann−Whitney test. Significant statistical differences are represented as * (p < 0.05) for comparison between
groups and naiv̈e mice. Key: NPs, nanoparticles; CS, chitosan; DS, dextran sulfate; PCS5, protease cleavage site 5; pIC, poly(I:C)
(polyinosinic:polycytidylic acid); HA, hyaluronic acid.
Figure 9. Change in CD4+ and CD8+ central memory and effector memory T cells. The amount of CD4+ and CD8+ T cell subsets expressing
(A, C) CD44+ CD62L− (T effector memory − TEM) and (B, D) CD44+ CD62L+ (T central memory − TCM)) was quantified by multicolor
flow cytometry of splenocytes from naiv̈e (red bars) and NP-vaccinated mice: CS/DS + PCS5 (black bars), CS−PCS5/DS/pIC (white bars)
or CS/HA−PCS5/pIC (gray bars). Values represent mean ± SEM (n ≥ 3). Statistical comparison between groups was done using a Mann−
Whitney test. Significant statistical differences are represented as * (p < 0.05) and ** (p < 0.01) for comparison between groups. Key: NPs,
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indicate that the three prototypes generated a modest number
of memory T cells for up to several weeks after the last boost.
In general, the highest proportions of memory T cells
corresponded to CS/HA−PCS5/pIC NPs and CS/DS +
PCS5 NPs, both at shorter and later time points.
Overall, the three prototypes of NPs showed the ability to
generate important antibody responses (Figure 6B), whereas
the ones containing PCS5 conjugated (CS/HA−PCS5/pIC
NPs and CS−PCS5/DS/pIC NPs) activated APCs in a higher
extent (Figure 7). In terms of cellular activation, all prototypes
were able to increase the secretion of important cytokines such
as IL-2 and TNFα, although the production kinetics varied
depending on the prototype (Figure 8). The implications of
these secretion patterns in the protection against infection is a
subject that has to be further analyzed.
CONCLUSIONS
In the present study, we engineered different polysaccharide-
based NPs loaded with an HIV peptide antigen candidate,
PCS5. The results showed that different factors, such as the
attachment of the antigen (ionic interactions and cleavable and
noncleavable conjugations), the presence of immunomodula-
tory molecules such as poly(I:C), or the nature of the
polysaccharides (CS, DS, or HA) could importantly influence
the type of the elicited immune response. All of the
nanosystems showed the ability to induced humoral responses
against the antigen, while for the kinetics of the effector T cell
responses varied depending on the prototype. In summary,
composition, antigen attachment, and adjuvants are important
design aspects that need to be considered when developing
nanovaccines. Further in vivo studies would be needed to
evaluate whether these humoral and cellular responses would
translate into efficient protection in larger animal models.
MATERIALS AND METHODS
Materials. Good manufacturing practice grade chitosan (CS)
(chlorhydrate salt, molecular weight (MW) 42.7 kDa and an 88%
deacetylation degree) was purchased from HMC+ (Germany).
Pharmaceutical grade dextran sulfate (DS), (sodium salt, MW 8
kDa) was obtained from Sigma-Aldrich SAFC (USA). Pharmaceutical
grade sodium hyaluronate (HA) (MW 57 kDa) was purchased from
Lifecore Biomedical (USA). Poly(I:C) HMW was acquired from
InvivoGen (USA), and high purity α,α-trehalose dihydrate was
purchased from Pfanstiehl (USA).
HIV PCS5 peptide (GPWGKKPRNFPMAQVHQGLM, MW 2280
Da and >95% purity), with or without a terminal cysteine residue, was
purchased from GenScript (USA).
MES hydrate, N-(2-aminoethyl)maleimide trifluoroacetate salt
(ASEM), N-hydroxysuccinimide (NHS), and N-(3-(dimethylamino)-
propyl)-N-ethylcarbodiimide hydrochloride (EDC) were obtained
from Sigma-Aldrich (USA).
Bio-Plex Pro Magnetic COOH Beads and Bio-Plex Amine
Coupling Kit were purchased from Bio-Rad (USA). Phycoerythrin-
labeled mouse antimonkey IgG was obtained from Southern Biotech
(USA), and PCS5 monoclonal antibody was donated by National
Microbiology Laboratory (Canada).
Screening of Blank Nanoparticles. The preparation method for
all of the NPs in this study was ionic complexation, based on the
interactions between the oppositely charged polymers: CS and DS or
CS and HA.
For CS/DS NPs, mass ratios from 3:1 to 1:3 were screened. Equal
volumes (0.825 mL) of an aqueous solution of CS (concentration
from 1.875 to 0.625 mg/mL) and aqueous solution of DS
(concentration from 0.625 to 1.875 mg/mL) were mixed under
mild magnetic stirring. The solutions were kept under magnetic
stirring for 10 min.
In the case of CS/HA NPs, mass ratios from 1.5:1 to 1:4 were
screened. Equal volumes (0.550 mL) of an aqueous solution of CS
(concentrations from 2.40 to 0.80 mg/mL) and aqueous solution of
HA (concentration from 1.60 to 3.20 mg/mL) were mixed under mild
magnetic stirring. The solution was stirred for an additional 10 min.
Synthesis of CS/DS + PCS5 NPs. CS/DS NPs at a 1:3 mass ratio
were prepared as previously described39 but with materials of a higher
quality grade. Briefly, 0.055 mL of PCS5 in aqueous solution (4 mg/
mL) was added to 0.770 mL of a CS aqueous solution (0.67 mg/mL)
under mild magnetic stirring. After being stirred for 5 min, 0.825 mL
of a DS aqueous solution (1.875 mg/mL) was also added. The
solution was stirred for an additional 5 min, and the formulation was
kept for 10 min without stirring prior to characterization.
Determination of PCS5 Association Efficiency. CS/DS +
PCS5 NPs were isolated by size-exclusion chromatography (SEC)
using CentriPure P10 gel filtration columns (emp Biotech GmbH,
Germany). The columns were first washed and stabilized with 15 mL
of ultrapure water, and then, 1 mL of NPs was transferred to the
column and allowed to enter the gel bed completely. After the void
volume was discarded, 2 mL of ultrapure water were added to the
column, and the isolated NPs were collected. The association
efficiency (AE) was calculated by comparing the amount of PCS5
associated with the NPs with the initial amount added to prepare the
NPs (eq 1). For this purpose, isolated NPs from SEC were treated to
a final KCl concentration of 2 M to break the ionic interactions
between the components of the NPs. Samples were analyzed by ultra
performance liquid chromatography (UPLC) on an Acquity H-UPLC
Class system with a Tunable UV (TUV) detector (Waters
Corporation, USA) equipped with an Aeris 3.6 μm Widepore XB-
C18 LC 100 × 2.1 mm Column (Phenomenex, USA). Mobile phase
A consisted of 0.1% trifluoroacetic acid (v/v) in ultrapure water and
phase B of 0.1% trifluoroacetic acid (v/v) in acetonitrile HPLC
gradient. The column temperature was set at 30 °C, and the run from
10% to 100% of phase B in 5 min. The amount of PCS5 in each
sample was calculated using a standard curve generated with known
concentrations of the peptide (6.5−100 μg/mL, r2 = 0.99).
= ×AE (%) amount of PCS5 recovered from SEC
amount of PCS5 added during preparation
100
(1)
Preparation of CS−PCS5/DS/pIC NPs. The conjugate CS−
PCS5 was purchased from Pepscan. PAoa-Ahx-PCS5-OH was
synthesized using standard solid-phase peptide chemistry through
Fmoc/tBu chemistry and subsequently purified to specifications using
reversed-phase preparative HPLC.
On the other hand, CS was dissolved in buffer (10 mM phosphate
buffer at pH 6.5), while N-succinimidyl 4-formylbenzoate (S-4FB)
was dissolved in dry dimethyl sulfoxide (DMSO) to generate a stock
of 30 mg/mL. A 50 μL portion of the S-4FB stock was added
dropwise to the CS solution (10 mg/mL in phosphate buffer), and the
reaction mixture was stirred overnight to allow for the coupling of the
S-4FB linker to the free amine residues in the CS. This derivatized CS
was then desalted using dialysis against phosphate buffer. Next, a
peptide aqueous solution at pH 6 was added to the activated CS
solution and allowed to conjugate overnight with agitation. The
resulting conjugate was then subjected to dialysis against phosphate
buffer to remove the unbound peptide.
The ratio of PCS5/CS was determined by a colorimetric assay.
First, 2-hydrazinopyridine was added to react with the S-4FB
incorporated to CS. Following incubation at 37 °C for 30 min, the
chromophoric bis-arylhydrazone obtained was quantified at 350 nm.
The difference between the amount of free linker before and after
PCS5 conjugation was considered the value of the substitution degree.
CS, PCS5, and CS−PCS5 samples were diluted in D2O water and
analyzed in a Varian Inova 750 spectrometer for 1H NMR, processed
using MestreNova (MESTRELAB).
For the preparation of these NPs, a mass ratio 2:1 CS/DS was
selected. A 0.0385 mL portion of an aqueous solution of the modified
CS (8.8 mg/mL) was added to a CS aqueous solution of 0.909 mg/
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mL to obtain a solution containing 2 mg/mL of CS and 0.2 mg/mL of
PCS5. Simultaneously, 2.5 μL of poly(I:C) (1 mg/mL) was then
added to 0.250 mL of an aqueous solution of DS (1 mg/mL), and this
solution was poured over 0.250 mL of the previous CS solution (2
mg/mL CS and 0.2 mg/mL of PCS5) under magnetic stirring for 10
min.
Synthesis of CS/HA−PCS5/pIC NPs. The PCS5 peptide was
linked to HA by a thiol−maleimide conjugation reaction, adapting a
recently described protocol.80 First, HA was diluted in MES buffer
(0.1 N, pH 6) to a concentration of 2 mg/mL, and ASEM, NHS, and
EDC in the same buffer solution were added at a concentration 6-,
14-, and 143-fold times higher than HA, respectively. The solution
was kept under magnetic stirring for 4 h at room temperature and
then dialyzed for 24 h to remove free reactives (SnakeSkin, cellulose
membrane MW 7 kDa, Thermo, Spain). In a second step, 0.228 mL
of PCS5 with a terminal cysteine residue in aqueous solution (5 mg/
mL) were poured over 5 mL of the solution of HA−ASEM (1 mg/
mL) in buffer (MES 0.1 N, NaCl 100 mM) under magnetic stirring.
The solution was kept under stirring for 4 h and then dialyzed for 24
h. Finally, the modified HA solution was frozen at −20 °C and freeze-
dried.
NMR analyses of HA, PCS5, and HA−PCS5 were conducted to
characterize the link and determine the substitution degree and the
yield. For this purpose, freeze-dried samples were resuspended in D2O
and analyzed using a Varian Inova 750 spectrometer for 1H NMR and
diffusion-ordered spectroscopy (DOSY). Then the NMR spectra were
processed using MestreNova (MESTRELAB). The degree of
substitution (DS) was calculated as the amount of PCS5 conjugated
per amount of HA, while the yield was determined by comparing the
amount of PCS5 conjugated to the total amount added to the reaction
(eq 2).
= ×yield (%)
amount of PCS5 conjugated to HA
initial amount of PCS5
100
(2)
NPs were formed at a 1:1 CS/HA mass ratio. Aqueous solutions of
either HA or HA−PCS5 at 2 mg/mL were prepared, and the ratio
between the two solutions adjusted to a final PCS5 peptide
concentration of 0.20 mg/mL. Poly(I:C) was also added as a 1
mg/mL aqueous solution to a final concentration of 2 μg/mL. Later,
0.55 mL of this HA and poly(I:C) solution (2 mg/mL, 2 μg/mL)
were poured over 0.55 mL of a CS aqueous solution (2 mg/mL)
under magnetic stirring and kept stirring for 10 min.
Nanoparticle Characterization. The mean size and polydisper-
sity index (PDI) of the NPs were characterized by dynamic light
scattering (DLS). The zeta potential values of the NPs were
determined by Laser Doppler Anemometry (LDA), measuring the
mean electrophoretic mobility after a 10-times dilution of the NPs in
ultrapure water. Both properties were measured using a Zetasizer
NanoZS (Malvern Instruments, United Kingdom). The measure-
ments were performed at 25 °C with a detection angle of 173°.
The PCS5 peptide loading capacity was determined by calculating
the real amount of PCS5 associated with the NPs (theoretical mass ×
AE%) relative to the real mass of the formulation, represented in eq 3.
Poly(I:C) loading values were calculated according to eq 4.
= × ×peptide loading (%) theoretical mass of PCS5 AE%
real mass of the formulation
100
(3)
= ×poly(I:C) loading (%)
theoretical mass of poly(I:C)
real mass of the formulation
100
(4)
Morphological Analysis. Morphological analysis of the suspen-
sion of NPs was conducted by field emission scanning electron
microscopy (FESEM) (Zeiss Gemini Ultra Plus, Germany). NPs were
diluted 1:100 in water and then with the same volume of
phosphotungstic acid (2% in water). A volume of 1 μL of sample
was placed on a copper grid with carbon films and allow to dry. Then
the grids were washed with water and analyzed under the microscope
once dried. STEM and immersion lens (InLens) detectors were used
to observe the samples.
Nanoparticle Surface Analysis by X-ray Photoelectron
Spectroscopy (XPS). The surface of CS/HA/pIC and CS/HA−
PCS5/pIC NPs was analyzed to confirm the presence of PCS5. A
droplet of each NP suspension was placed on a silicon wafer, used as
sample holder, and then allowed to dry in a desiccator overnight. For
the reference materials (CS, HA, and PCS5), a small quantity of
powder was pressed onto a conductive double side adhesive tape on
the standard sample holder.
Samples were analyzed by angle-resolved XPS using the ESCALAB
250 iXL instrument (Thermo Scientific K-Alpha ESCA, Thermo
Scientific, UK), and photoelectrons were collected from a takeoff
angle of 45◦ relative to the sample surface. Monochromatic X-ray
source Al Kα (1486.6 eV) was used for experiments and spectra were
acquired at 10−10 mbar. Surface elemental composition was
determined using the standard Scofield photoemission cross section.
The binding energies positions on unsputtered surfaces were
calibrated by setting the C1s photopeak corresponding to aliphatic
carbon at 285.0 eV. The atomic concentrations were determined from
the XPS peak areas using the Shirley background subtraction
technique and the Scofield sensitivity factors.
PCS5 Release in Glutathione-Rich Media. CS/HA−PCS5/pIC
NPs were incubated at 37 °C up to 8 h in PBS with a 10 mM
concentration of reduced glutathione (GSH). In parallel, as a control,
NPs were incubated in PBS under the same conditions. At the
different time-points, NPs were centrifuged for 10 min at 16000 g to
break the NPs and collect the HA−PCS5 from the supernatant. Later,
1 N HCl was added to the supernatant to lower the pH to 2, in order
to avoid interactions between the free peptide (pI 11) and the
conjugate HA−PCS5 (pKa 3), and to prevent that any remaining
GSH kept reacting. Samples were analyzed by UPLC, as described for
PCS5, but with a run from 10% to 50% of phase B in 20 min. The
amount of free PCS5 peptide and conjugated PCS5 in each sample
was calculated using a standard curve generated with known
concentrations of the peptide and conjugate (6−50 μg/mL, r2 =
0.99).
Freeze-Drying. Nanoparticles were frozen in the presence of the
cryoprotectant agent trehalose at −80 °C for at least 2 h and then
freeze-dried (Genesis 25 EL, S.P Industries, USA). Lyophilization was
done at a temperature ranging from −40 to +20 °C, applying a
progressive vacuum from 200 to 20 mTorr. After this process, NPs
were resuspended in water and their physicochemical properties
determined by DLS and LDA as previously described.
Animal Care. Female BALB/c mice 6−8 weeks old were obtained
from Charles River Laboratories (Wilmington, MA. USA) and housed
at the Veterinary Technical Service unit of National Microbiology
Laboratory (Winnipeg, Manitoba). A maximum of five animals were
housed per cage in a level 2 facility. All animals used in the project
were treated in a humane manner in accordance with the Principles of
the Canadian Council on Animal Care contained in the “Guide to the
Care and Use of Experimental Animals”. All animal procedures were
performed by highly trained personnel using approved techniques. All
mice were anesthetized by inhalation of 3−5% isofluorane, and all
possible efforts were made to minimize the pain and discomfort of the
animals. Euthanization of animals was conducted using an excess
amount of the anesthetic.
Murine Experiments. Eighty female BALB/c mice were divided
into four categories. Five unvaccinated mice (week 0) were used as a
control. The rest of the mice were divided into three groups of 25
animals each. Mice were intramuscularly injected with 50 μL of the
resuspended freeze-dried NPs (CS/DS + PCS5, CS/HA−PCS5/pIC
and CS−PCS5/DS/pIC) at 0, 4, and 8 weeks. Each group of
vaccinated animals was kept in a separate cage and monitored every
24 h for feeding, water drinking, and weight loss.
Plasma Antibody Quantification. Plasma was separated from
whole blood collected from mice using saphenous bleeding, by
centrifugation at 2000 g for 10 min. Mouse plasma samples were
collected at 2, 4, 8, 9, 10, 12, 14, and 16 weeks following vaccination,
and the concentrations of PCS5-specific plasma IgG antibodies were
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quantified using a previously published protocol.39 Briefly, 20 μg of
PCS5 was coupled to 1.25 × 106 Bio-Plex Pro Magnetic COOH
Beads using a Bio-Plex Amine Coupling Kit. 50 μL of plasma (1:80
diluted) were incubated with 2,500 beads. SIV-specific IgG was
detected with phycoerythrin-labeled mouse antimonkey IgG at 5 μg/
mL. Bead fluorescence intensities were acquired on the Bio-Plex 200
system and converted to concentrations as previously described.39
Splenocytes Response Quantification. Five mice per group
were sacrificed at 0 (naiv̈e mice) 9, 10, 12, 14, and 16 weeks
(vaccinated mice), and their spleens were collected. Splenocytes were
purified by straining of spleens through a 40 μm nylon mesh. The
resulting mixtures were suspended in R10 media containing RPMI-
1640 complemented with 10% fetal bovine serum (FBS) and 2%
antibiotic−antimycotic solutions. The splenocytes were then frozen in
freezing media consisting of 95% FBS and 5% DMSO. Half a million
splenocytes were transferred into 12 × 75 mm polypropylene BD
Falcon tubes for flow cytometry antibody labeling. Alternatively, 5.0 ×
105 splenocytes were stimulated separately with a 5 μg/mL
suspension of a pool of PCS5 peptides: PCS5-1 (GPWGKKPRNF-
PMAQVHQGLM), PCS5-2 (YGQMPRQTGGFFRPWSMGKE), or
PCS5-3 (KPRNFPMAQVHQGLM) peptides. Peptide stimulated and
unstimulated splenocytes were washed using PBS with 2% FBS at
1500 rpm for 5 min. The washed splenocytes were surface stained
with either a T-cell or monocyte/macrophage cocktails of antibodies
for 30 min in the dark and at room temperature. The stained cells
were washed using 5% PBS followed by addition of 150 μL of BD
Cytofix/Cytoperm and a 10 min incubation in the dark. Following the
incubation, permeabilized cells were washed using 1× BD Permwash
solution followed by intracellular cytokine staining (ICS) for 30 min
in the dark. After ICS, cells were washed using 1× BD PermWash and
then run on LSRII flow cytometer. Data acquisition was done using
BD FACSDiva software and analyzed using FlowJo (Treestar, Inc.,
USA).
Statistics. Data analysis was performed using GraphPad Prism
version 7.0 (GraphPad Inc.). Comparison of group data was
performed with a Mann−Whitney test. Data was expressed as the
mean ± standard error of the mean (SEM). p values of 0.05 or less
were considered statistically significant.
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(22) Zupancǐc,̌ E.; Curato, C.; Paisana, M.; Rodrigues, C.; Porat, Z.;
Viana, A. S.; Afonso, C. A. M.; Pinto, J.; Gaspar, R.; Moreira, J. N.;
Satchi-Fainaro, R.; Jung, S.; Florindo, H. F. Rational Design of
Nanoparticles towards Targeting Antigen-Presenting Cells and
Improved T Cell Priming. J. Controlled Release 2017, 258, 182−195.
(23) Shi, G.-N.; Zhang, C.-N.; Xu, R.; Niu, J.-F.; Song, H.-J.; Zhang,
X.-Y.; Wang, W.-W.; Wang, Y.-M.; Li, C.; Wei, X.-Q.; Kong, D.-L.
Enhanced Antitumor Immunity by Targeting Dendritic Cells with
Tumor Cell Lysate-Loaded Chitosan Nanoparticles Vaccine. Bio-
materials 2017, 113, 191−202.
(24) Vicente, S.; Diaz-Freitas, B.; Peleteiro, M.; Sanchez, A.; Pascual,
D. W.; Gonzalez-Fernandez, A.; Alonso, M. J. A Polymer/Oil Based
Nanovaccine as a Single-Dose Immunization Approach. PLoS One
2013, 8, 2−9.
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